NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

RNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in ...

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

It is common for sponsors to switch digital platforms between clinical trial phases, but sponsors can achieve much by using ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...